Systematic review on EGFR alterations in recurrent glioblastoma therapy response
The review assesses the predictive value of EGFR amplification and EGFRvIII mutation for EGFR-targeted therapy in recurrent glioblastoma.
Asset / Drug
Drug and asset intelligence for Systematic with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.